Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C

In the phase III AZA-001 trial, low-dose cytarabine (LDara-C), the most widely used low-dose chemotherapy in patients with higher-risk myelodysplastic syndrome (MDS) who are ineligible for intensive treatment, was found to be associated with poorer survival compared with azacitidine. This analysis f...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Fenaux, Pierre, Gattermann, Norbert, Seymour, John F., Hellström-Lindberg, Eva, Mufti, Ghulam J., Duehrsen, Ulrich, Gore, Steven D., Ramos, Fernando, Beyne-Rauzy, Odile, List, Alan, McKenzie, David, Backstrom, Jay, Beach, Charles L.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2010
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4000023/
https://ncbi.nlm.nih.gov/pubmed/20136825
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2010.08082.x
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia